Destiny Pharma PLC Directorate Change (0610S)

TIDMDEST

RNS Number : 0610S

Destiny Pharma PLC

21 June 2018

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma appoints Nick Rodgers as Non-Executive Director

Brighton, United Kingdom - 21 June 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces the appointment of Nick Rodgers as an independent Non-Executive Director with immediate effect.

Nick Rodgers has considerable Board experience in both public and private growth companies, particularly those in the life science sector, as well as a background as a successful corporate financier and investment banker. Nick is currently chairman of SEHTA, one of the largest health technology networking organisations in the UK. Prior to this, he was non-executive director and then chairman of fully listed Oxford Biomedica plc, a leading gene-based biopharmaceutical company, from 2004 until 2016. Previously. Nick headed up both the Life Science and Corporate Finance department at Evolution Beeson Gregory (now Investec) advising many life science listed companies from 1989 until 2003.

Sir Nigel Rudd, Chairman of Destiny Pharma commented:

"We are very pleased to announce Nick's appointment to our Board. His experience of guiding growth companies, and in particular those in the life science sector will be invaluable as Destiny Pharma expands its activities and continues to advance its lead drug candidate, XF-73, through clinical development."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Philip Nicholas (Nick) Rodgers, aged 59 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current                              Past 
 
 Nick Rodgers Financial Limited       Oxford BioMedica 
                                       plc 
 Productiv Limited 
 Productiv Property Ltd 
 Productiv Technology Ltd (dormant) 
 The Proving Factory Ltd (dormant) 
 South East Health Technologies 
  Alliance Ltd 
 Alcuris Limited 
 Zapinamo Limited 
 Interactive Me Limited 
 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Simon Sacerdoti, CFO

[e-mail]

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail]

[phone]

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

Philip Davies / Will Goode, Corporate Finance

Andrew Keith, Healthcare Equity Sales

[phone]

finnCap Ltd (Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOABRGDLCSDBGIG

(END) Dow Jones Newswires

June 21, 2018 02:00 ET (06:00 GMT)